Tony Wood

Stories

FDA approves Jemperli for certain rectal cancers, allowing many patients to skip surgery and chemo

Announced the October 2026 approval

The FDA granted accelerated approval to Jemperli (dostarlimab) on October 19 for adults with a genetic subtype of locally advanced rectal cancer. It is the first immunotherapy cleared for these patients, and trial data show most can skip chemotherapy, radiation and surgery.

Updated Oct 23